Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (317)
Quality standard (30)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (2)
Highly specialised technologies guidance (1)
Interventional procedures guidance (18)
Medical technologies guidance (7)
Technology appraisal guidance (287)
Apply filters
Showing 101 to 150 of 347
Guidance and quality standards awaiting development
Title
Type
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis TS ID 11869
Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046
Technology appraisal guidance
Electrically stimulated intravesical therapy for Interstitial Cystitis
Interventional procedures guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847
Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917
Technology appraisal guidance
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction
Interventional procedures guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718
Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]
Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015
Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037
Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Technology appraisal guidance
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920
Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]
Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]
Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Technology appraisal guidance
Galcanezumab for migraine TS ID 10663
Technology appraisal guidance
Gambling
Quality standard
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394
Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]
Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772
Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Technology appraisal guidance
Gout
Quality standard
Heart valve disease in adults
Quality standard
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]
Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330
Technology appraisal guidance
IgPro20 for treating dermatomyositis TS ID 12014
Technology appraisal guidance
In-situ Normothermic Regional Perfusion system for DCD donors
Interventional procedures guidance
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990
Technology appraisal guidance
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430
Technology appraisal guidance
Infant, children and young people's experience of health care
Quality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Technology appraisal guidance
Insertion of a Catheter based intravascular microaxial blood pump for acute heart failure
Interventional procedures guidance
Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention
Interventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190
Technology appraisal guidance
Iptacopan for treating complement 3 glomerulopathy TS ID 10435
Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949
Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Technology appraisal guidance
Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease
Interventional procedures guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]
Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822
Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmias
Interventional procedures guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Technology appraisal guidance
Previous page
1
2
Current page
3
4
5
…
7
Page
3
of
7
Next page
Results per page
10
25
50
All
Back to top